Eosinophils are the dominant type2 marker for the current indication of biological treatment in severe uncontrolled chronic rhinosinusitis with nasal polyps
Volume: 62 - Issue: 3
First page: 383 - Last page: 384
R. van der Lans - J.J. Otten - G.F.J.P.M. Adriaensen - L.B.L. Benoist - M.E. Cornet - D.R. Hoven - A.B. Rinia - W.J. Fokkens - S. Reitsma
DOI: 10.4193/Rhin23.081
The latest European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS2020) defines markers for type2 inflammation in the context of indicating biological therapy in severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) as either a total serum immunoglobulin E (total-IgE)
Rhinology 62-3: 383-384, 2024
